It is worthy to note that another EGFR-directed clinical trial testing cetuximab as adjuvant therapy with gemcitabine in patients with advanced pancreatic adenocarcinoma did not improve the overall survival compared with patients treated with gemcitabine alone [163, 164]. The gene discussed is EGFR; the disease is pancreatic adenocarcinoma.